Nanoviricides (NNVC) Return on Capital Employed (2011 - 2026)
Nanoviricides (NNVC) posted Return on Capital Employed of 80.33% for Q1 2026, up 12.77% sequentially from 92.08% in Q4 2025, and up 2243.0% YoY from 3.43% in Q1 2025.
Nanoviricides (NNVC) Return on Capital Employed (2011 - 2026) Analysis & Trends
Nanoviricides has reported Return on Capital Employed for 16 years, with the latest figure at 80.33% in Q1 2026.
- Quarterly Return on Capital Employed rose 2243.0% year-over-year to 80.33% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 80.33% (up 2243.0% YoY) and the FY2025 annual result came in at 100.78%, down 3771.0% from the prior year.
- Return on Capital Employed grew to 80.33% in Q1 2026 per NNVC's latest filing, from 92.08% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 31.99% in Q3 2022 and troughed at 118.1% in Q2 2025.
- A 5-year average of 70.84% and a median of 78.96% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed tumbled 4740 bps in 2024, then soared 2243 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 33.92% in 2022, then slumped by 113 bps to 72.1% in 2023, then dropped by 26 bps to 90.98% in 2024, then decreased by 1 bps to 92.08% in 2025, then rose by 13 bps to 80.33% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 80.33%, 92.08%, and 110.96% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 7.88% |
| 10 | Nanoviricides | 29.17 Mn | 25.96 Mn | - | -80.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -80.33% |
| Dec 31, 2025 | -92.08% |
| Sep 30, 2025 | -110.96% |
| Jun 30, 2025 | -118.10% |
| Mar 31, 2025 | -102.76% |
| Dec 31, 2024 | -90.98% |
| Sep 30, 2024 | -90.64% |
| Jun 30, 2024 | -78.96% |
| Mar 31, 2024 | -84.35% |
| Dec 31, 2023 | -72.10% |
| Sep 30, 2023 | -61.49% |
| Jun 30, 2023 | -51.98% |
| Mar 31, 2023 | -36.95% |
| Dec 31, 2022 | -33.92% |
| Sep 30, 2022 | -31.99% |
| Jun 30, 2022 | -33.94% |
| Mar 31, 2022 | -32.81% |
| Dec 31, 2021 | -31.52% |
| Sep 30, 2021 | -31.49% |
| Jun 30, 2021 | -28.06% |